Selected research
Industry Research
IL-4Rα Targeting Drugs Industry Research Report 2026
Market perspective
The global IL-4Rα Targeting Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for IL-4Rα Targeting Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for IL-4Rα Targeting Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for IL-4Rα Targeting Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of IL-4Rα Targeting Drugs include AstraZeneca, Innovent Biologics, Numab Therapeutics, Regeneron, Sanofi, Hengrui Medical, Kengfang Biopharmaceuticals, Connaide Biopharmaceuticals and Conoya Biopharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global IL-4Rα Targeting Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
IL-4Rα Targeting Drugs Market by Company
AstraZeneca
Innovent Biologics
Numab Therapeutics
Regeneron
Sanofi
Hengrui Medical
Kengfang Biopharmaceuticals
Connaide Biopharmaceuticals
Conoya Biopharmaceuticals
Qingzhixiang Jintai Biopharmaceuticals
Sunshine Guojian
IL-4Rα Targeting Drugs Segment by Type
Small Molecule Inhibitors
Fusion Proteins
Monoclonal Antibodies
Vaccines
IL-4Rα Targeting Drugs Segment by Application
Chronic Sinusitis with Nasal Polyps
Atopic Dermatitis
Asthma
Other
IL-4Rα Targeting Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IL-4Rα Targeting Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of IL-4Rα Targeting Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IL-4Rα Targeting Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of IL-4Rα Targeting Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of IL-4Rα Targeting Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of IL-4Rα Targeting Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Small Molecule Inhibitors
- Fusion Proteins
- Monoclonal Antibodies
- Vaccines
Applications
- Chronic Sinusitis with Nasal Polyps
- Atopic Dermatitis
- Asthma
- Other
Companies covered
- AstraZeneca
- Innovent Biologics
- Numab Therapeutics
- Regeneron
- Sanofi
- Hengrui Medical
- Kengfang Biopharmaceuticals
- Connaide Biopharmaceuticals
- Conoya Biopharmaceuticals
- Qingzhixiang Jintai Biopharmaceuticals
- Sunshine Guojian
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global IL-4Rα Targeting Drugs Market Size (2021-2032)
- 2.2.2 Global IL-4Rα Targeting Drugs Sales (2021-2032)
- 2.2.3 Global IL-4Rα Targeting Drugs Market Average Price (2021-2032)
- 2.3 IL-4Rα Targeting Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Small Molecule Inhibitors
- 2.3.3 Fusion Proteins
- 2.3.4 Monoclonal Antibodies
- 2.3.5 Vaccines
- 2.4 IL-4Rα Targeting Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Chronic Sinusitis with Nasal Polyps
- 2.4.3 Atopic Dermatitis
- 2.4.4 Asthma
- 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global IL-4Rα Targeting Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global IL-4Rα Targeting Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global IL-4Rα Targeting Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global IL-4Rα Targeting Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global IL-4Rα Targeting Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of IL-4Rα Targeting Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of IL-4Rα Targeting Drugs, Product Type & Application
- 3.8 Global Manufacturers of IL-4Rα Targeting Drugs, Established Date
- 3.9 Global IL-4Rα Targeting Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 AstraZeneca
- 4.1.1 AstraZeneca Company Information
- 4.1.2 AstraZeneca Business Overview
- 4.1.3 AstraZeneca IL-4Rα Targeting Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 AstraZeneca IL-4Rα Targeting Drugs Product Portfolio
- 4.1.5 AstraZeneca Recent Developments
- 4.2 Innovent Biologics
- 4.2.1 Innovent Biologics Company Information
- 4.2.2 Innovent Biologics Business Overview
- 4.2.3 Innovent Biologics IL-4Rα Targeting Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Innovent Biologics IL-4Rα Targeting Drugs Product Portfolio
- 4.2.5 Innovent Biologics Recent Developments
- 4.3 Numab Therapeutics
- 4.3.1 Numab Therapeutics Company Information
- 4.3.2 Numab Therapeutics Business Overview
- 4.3.3 Numab Therapeutics IL-4Rα Targeting Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Numab Therapeutics IL-4Rα Targeting Drugs Product Portfolio
- 4.3.5 Numab Therapeutics Recent Developments
- 4.4 Regeneron
- 4.4.1 Regeneron Company Information
- 4.4.2 Regeneron Business Overview
- 4.4.3 Regeneron IL-4Rα Targeting Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Regeneron IL-4Rα Targeting Drugs Product Portfolio
- 4.4.5 Regeneron Recent Developments
- 4.5 Sanofi
- 4.5.1 Sanofi Company Information
- 4.5.2 Sanofi Business Overview
- 4.5.3 Sanofi IL-4Rα Targeting Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Sanofi IL-4Rα Targeting Drugs Product Portfolio
- 4.5.5 Sanofi Recent Developments
- 4.6 Hengrui Medical
- 4.6.1 Hengrui Medical Company Information
- 4.6.2 Hengrui Medical Business Overview
- 4.6.3 Hengrui Medical IL-4Rα Targeting Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Hengrui Medical IL-4Rα Targeting Drugs Product Portfolio
- 4.6.5 Hengrui Medical Recent Developments
- 4.7 Kengfang Biopharmaceuticals
- 4.7.1 Kengfang Biopharmaceuticals Company Information
- 4.7.2 Kengfang Biopharmaceuticals Business Overview
- 4.7.3 Kengfang Biopharmaceuticals IL-4Rα Targeting Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Kengfang Biopharmaceuticals IL-4Rα Targeting Drugs Product Portfolio
- 4.7.5 Kengfang Biopharmaceuticals Recent Developments
- 4.8 Connaide Biopharmaceuticals
- 4.8.1 Connaide Biopharmaceuticals Company Information
- 4.8.2 Connaide Biopharmaceuticals Business Overview
- 4.8.3 Connaide Biopharmaceuticals IL-4Rα Targeting Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Connaide Biopharmaceuticals IL-4Rα Targeting Drugs Product Portfolio
- 4.8.5 Connaide Biopharmaceuticals Recent Developments
- 4.9 Conoya Biopharmaceuticals
- 4.9.1 Conoya Biopharmaceuticals Company Information
- 4.9.2 Conoya Biopharmaceuticals Business Overview
- 4.9.3 Conoya Biopharmaceuticals IL-4Rα Targeting Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Conoya Biopharmaceuticals IL-4Rα Targeting Drugs Product Portfolio
- 4.9.5 Conoya Biopharmaceuticals Recent Developments
- 4.10 Qingzhixiang Jintai Biopharmaceuticals
- 4.10.1 Qingzhixiang Jintai Biopharmaceuticals Company Information
- 4.10.2 Qingzhixiang Jintai Biopharmaceuticals Business Overview
- 4.10.3 Qingzhixiang Jintai Biopharmaceuticals IL-4Rα Targeting Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Qingzhixiang Jintai Biopharmaceuticals IL-4Rα Targeting Drugs Product Portfolio
- 4.10.5 Qingzhixiang Jintai Biopharmaceuticals Recent Developments
- 4.11 Sunshine Guojian
- 4.11.1 Sunshine Guojian Company Information
- 4.11.2 Sunshine Guojian Business Overview
- 4.11.3 Sunshine Guojian IL-4Rα Targeting Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Sunshine Guojian IL-4Rα Targeting Drugs Product Portfolio
- 4.11.5 Sunshine Guojian Recent Developments
5 Global IL-4Rα Targeting Drugs Market Scenario by Region
- 5.1 Global IL-4Rα Targeting Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global IL-4Rα Targeting Drugs Sales by Region: 2021-2032
- 5.2.1 Global IL-4Rα Targeting Drugs Sales by Region: 2021-2026
- 5.2.2 Global IL-4Rα Targeting Drugs Sales by Region: 2027-2032
- 5.3 Global IL-4Rα Targeting Drugs Revenue by Region: 2021-2032
- 5.3.1 Global IL-4Rα Targeting Drugs Revenue by Region: 2021-2026
- 5.3.2 Global IL-4Rα Targeting Drugs Revenue by Region: 2027-2032
- 5.4 North America IL-4Rα Targeting Drugs Market Facts & Figures by Country
- 5.4.1 North America IL-4Rα Targeting Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America IL-4Rα Targeting Drugs Sales by Country (2021-2032)
- 5.4.3 North America IL-4Rα Targeting Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe IL-4Rα Targeting Drugs Market Facts & Figures by Country
- 5.5.1 Europe IL-4Rα Targeting Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe IL-4Rα Targeting Drugs Sales by Country (2021-2032)
- 5.5.3 Europe IL-4Rα Targeting Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific IL-4Rα Targeting Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific IL-4Rα Targeting Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific IL-4Rα Targeting Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific IL-4Rα Targeting Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America IL-4Rα Targeting Drugs Market Facts & Figures by Country
- 5.7.1 South America IL-4Rα Targeting Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America IL-4Rα Targeting Drugs Sales by Country (2021-2032)
- 5.7.3 South America IL-4Rα Targeting Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa IL-4Rα Targeting Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa IL-4Rα Targeting Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa IL-4Rα Targeting Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa IL-4Rα Targeting Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global IL-4Rα Targeting Drugs Sales by Type (2021-2032)
- 6.1.1 Global IL-4Rα Targeting Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global IL-4Rα Targeting Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global IL-4Rα Targeting Drugs Revenue by Type (2021-2032)
- 6.2.1 Global IL-4Rα Targeting Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global IL-4Rα Targeting Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global IL-4Rα Targeting Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global IL-4Rα Targeting Drugs Sales by Application (2021-2032)
- 7.1.1 Global IL-4Rα Targeting Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global IL-4Rα Targeting Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global IL-4Rα Targeting Drugs Revenue by Application (2021-2032)
- 7.2.1 Global IL-4Rα Targeting Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global IL-4Rα Targeting Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global IL-4Rα Targeting Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 IL-4Rα Targeting Drugs Value Chain Analysis
- 8.1.1 IL-4Rα Targeting Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 IL-4Rα Targeting Drugs Production Mode & Process
- 8.2 IL-4Rα Targeting Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 IL-4Rα Targeting Drugs Distributors
- 8.2.3 IL-4Rα Targeting Drugs Customers
9 Global IL-4Rα Targeting Drugs Analyzing Market Dynamics
- 9.1 IL-4Rα Targeting Drugs Industry Trends
- 9.2 IL-4Rα Targeting Drugs Industry Drivers
- 9.3 IL-4Rα Targeting Drugs Industry Opportunities and Challenges
- 9.4 IL-4Rα Targeting Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst